| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
| US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 1 month from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(1 year, 7 months from now) | |
| US9233956 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
May, 2029
(5 years from now) | |
|
US9233956 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Nov, 2029
(5 years from now) | |
|
US7994185 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
|
US8415345 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(6 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(6 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(9 years from now) | |
| US11504333 | NOVARTIS | Pharmaceutical composition |
Jun, 2038
(14 years from now) | |
Tafinlar is owned by Novartis.
Tafinlar contains Dabrafenib Mesylate.
Tafinlar has a total of 15 drug patents out of which 0 drug patents have expired.
Tafinlar was authorised for market use on 29 May, 2013.
Tafinlar is available in capsule;oral, tablet, for suspension;oral dosage forms.
Tafinlar can be used as tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection, tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test., tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options, tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test., tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection.
Drug patent challenges can be filed against Tafinlar from 22 December, 2024.
The generics of Tafinlar are possible to be released after 29 June, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-908) | Mar 16, 2026 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-170) | Nov 20, 2018 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...
Dosage: CAPSULE;ORAL; TABLET, FOR SUSPENSION;ORAL
TAFINLAR family patents
